Baseline PET Metabolic Tumor Volume Predicts Outcome in Advanced Follicular Lymphoma Patients Who Received First-Line Immunochemotherapy but Not Those Treated with Lenalidomide-Rituximab in the Phase III Relevance Study

被引：0

作者：

Cottereau, Anne Segolene ^{[1
]}

Rebaud, Louis ^{[2
]}

Trotman, Judith ^{[3
]}

Feugier, Pierre ^{[4
]}

Nastoupil, Loretta J. ^{[5
]}

Bachy, Emmanuel ^{[6
]}

Flinn, Ian W. ^{[7
]}

Haioun, Corinne ^{[8
]}

Ysebaert, Loic ^{[9
]}

Bartlett, Nancy L. ^{[10
]}

Tilly, Herve ^{[11
]}

Casasnovas, Rene-Olivier ^{[12
]}

Ricci, Romain ^{[13
]}

Portugues, Cedric ^{[14
]}

Buvat, Irene ^{[15
]}

Meignan, Michel ^{[16
,17
]}

Morschhauser, Franck ^{[18
]}

机构：

[1] Cochin Univ Hosp, AP HP, Dept Nucl Med, Paris, France

[2] Inst Curie, Lab Imagerie Translat Oncol, U1288 Inserm, Paris, France

[3] Concord Hosp, Dept Haematol, Concord, Australia

[4] Univ Hosp Nancy, Hematol Dept, Vandoeuvre Les Nancy, France

[5] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX USA

[6] Lyon Sud Univ Hosp, Hosp Civils Lyon, Dept Hematol, Pierre Benite, France

[7] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA

[8] Univ Paris Est Creteil UPEC, Lymphoid Malignancies Dept, Henri Mondor Univ Hosp Assistance, Assistance Publ Hop Paris AP HP, Creteil, France

[9] Inst Univ Canc Toulouse Oncopole, Hematol Dept, Toulouse, France

[10] Washington Univ, Siteman Canc Ctr, Sch Med, St Louis, MO USA

[11] Ctr Henri Becquerel, Rouen, France

[12] CHU Dijon Bourgogne, Hematol Clin, Dijon, France

[13] Lymphoma Acad Res Org, LYSARC, Creteil, France

[14] Ctr Hosp Lyon Sud, Lymphoma Acad Res Org, LYSARC, Lyon, France

[15] Univ Paris Saclayr, Inst Curie, LITO Lab, UMR 1288 Inserm, Orsay, France

[16] CHU Henri Mondor, Creteil, France

[17] LYSA, Paris, France

[18] CHU Lille, Serv Malad Sang, Lille, France

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-159207

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：6474 / 6476

页数：3

共 21 条

[1] Baseline PET-Derived Metabolic Tumor Volume Metrics Did Not Predict Outcomes in Follicular Lymphoma Patients Treated with First-Line Immunochemotherapy and Antibody Maintenance in the Phase III GALLIUM Study
Barrington, Sally F.
Trotman, Judith
Sahin, Deniz
Belada, David
Davies, Andrew
MacEwan, Robert
Owen, Carolyn
Ptacnik, Vaclav
Rosta, Andras
Hiddemann, Wolfgang
Marcus, Robert
Nielsen, Tina
Mattiello, Federico
Zeuner, Harald
Meignan, Michel
BLOOD, 2018, 132
[2] Follicular Lymphoma Treated with First-Line Immunochemotherapy: A Review of PET/CT in Patients Who Did Not Achieve a Complete Metabolic Response in the GALLIUM Study
Barrington, Sally F.
Mir, Farheen
El-Galaly, Tarec Christoffer
Knapp, Andrea
Nielsen, Tina G.
Sahin, Denis
Wenger, Michael
Kostakoglu, Lale
Trotman, Judith
Meignan, Michel
JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (08) : 1149 - 1154
[3] Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial
Cottereau, A. S.
Rebaud, L.
Trotman, J.
Feugier, P.
Nastoupil, L. J.
Bachy, E.
Flinn, I. W.
Haioun, C.
Ysebaert, L.
Bartlett, N. L.
Tilly, H.
Casasnovas, O.
Ricci, R.
Portugues, C.
Buvat, I.
Meignan, M.
Morschhauser, F.
ANNALS OF ONCOLOGY, 2024, 35 (01) : 130 - 137
[4] Minimal Residual Disease in Patients with Follicular Lymphoma Treated with Obinutuzumab or Rituximab As First-Line Induction Immunochemotherapy and Maintenance in the Phase 3 GALLIUM Study
Pott, Christiane
Hoster, Eva
Kehden, Britta
Unterhalt, Michael
Herold, Michael
van der Jagt, Richard H.
Janssens, Ann
Kneba, Michael
Mayer, Jiri
Pocock, Chris
Danesi, Nathalie
Fingerle-Rowson, Gunter
Harbron, Chris
Mundt, Kirsten
Marcus, Robert E.
Hiddemann, Wolfgang
BLOOD, 2016, 128 (22)
[5] Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report
Tout, Mira
Casasnovas, Olivier
Meignan, Michel
Lamy, Thierry
Morschhauser, Franck
Salles, Gilles
Gyan, Emmanuel
Haioun, Corinne
Mercier, Melanie
Feugier, Pierre
Boussetta, Sami
Paintaud, Gilles
Ternant, David
Cartron, Guillaume
BLOOD, 2017, 129 (19) : 2616 - 2623
[6] Baseline total metabolic tumor volume assessed by 18FDG-PET/CT predicts outcome in advanced melanoma patients treated with pembrolizumab
Awada, G.
Ozdemir, I.
Schwarze, J. K.
Daeninck, E.
Gondry, O.
Jansen, Y.
Seremet, T.
Keyaerts, M.
Everaert, H.
Neyns, B.
ANNALS OF ONCOLOGY, 2018, 29
[7] Total Metabolic Tumor Volume And Tumor Dissemination Calculated From PET/CT Scan Before First Line Therapy Are Predictors Of Outcome In Patients With Follicular Lymphoma
Durmo, R.
Guerra, L.
Chauvie, S.
Peano, S.
Franceschetto, A.
Bergesio, F.
Fallanca, F.
Pinto, A.
Ghiggi, C.
Pulsoni, A.
Merli, M.
Farina, L.
Tani, M.
Boccomini, C.
Musuraca, G.
Falini, B.
Ballerini, F.
Stefani, P. M.
Bolis, S. A. M.
Pietrantuono, G.
Manni, M.
Marcheselli, L.
Federico, M.
Luminari, S.
Versari, A.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S210 - S211
[8] Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study
Cartron, Guillaume
Bachy, Emmanuel
Tilly, Herve
Daguindau, Nicolas
Pica, Gian-Matteo
Bijou, Fontanet
Mounier, Christiane
Clavert, Aline
Damaj, Gandhi Laurent
Slama, Borhane
Casasnovas, Olivier
Houot, Roch
Bouabdallah, Krimo
Sibon, David
Fitoussi, Olivier
Morineau, Nadine
Herbaux, Charles
Gastinne, Thomas
Fornecker, Luc-Matthieu
Haioun, Corinne
Launay, Vincent
Araujo, Carla
Benbrahim, Omar
Sanhes, Laurence
Gressin, Remy
Gonzalez, Hugo
Morschhauser, Franck
Ternant, David
Xerri, Luc
Tarte, Karin
Pranger, Delphine
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (19) : 3523 - +
[9] CELESTIMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab plus lenalidomide versus rituximab plus lenalidomide in patients with relapsed or refractory follicular lymphoma who have received ≥ 1 line of systemic therapy.
Nastoupil, Loretta J.
Morschhauser, Franck
Scholz, Christian W.
Bishton, Mark
Yoon, Sung-Soo
Giri, Pratyush
Wei, Michael C.
Knapp, Andrea
Li, Chi-Chung
Bottos, Alessia
Li, Haocheng
Purev, Enkhtsetseg
Bartlett, Nancy L.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[10] Phase III study of watchful waiting vs. rituximab as first-line treatment in advanced stage follicular lymphoma with low tumour burden (JCOG1411, FLORA study)
Miyamoto, Kenichi
Fukuhara, Noriko
Maruyama, Dai
Shibata, Taro
Nakamura, Kenichi
Ishizawa, Kenichi
Tsukasaki, Kunihiro
Nagai, Hirokazu
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 48 (08) : 777 - 780

← 1 2 3 →